/// Resources ///
News, Tools & Analysis
American biosecurity is contested on two fronts, and the debate moves fast. This is where ABI keeps the case in the open. Run the simulation. See who is on the record. Read what others are publishing. Follow the analysis.
/// Featured ///
The Policy Simulation
Interactive
Keep America Competitive and Secure
Compete and protect at the same time. Eight policy moves, each with a case and a cost. Some compound into strength. Some collapse into shortage. Weigh the choices and see where they leave the country.
Enter the Simulation/// Congress and the Administration ///
On the Record
When leaders in Congress and the administration speak to American biosecurity, we collect it here. Statements, testimony, and video, in their own words.
Content Pending Submissions
Sen. Jane Doe (R-State)
"American medicine is national security, and it is time we treated it that way."
Watch ›
Rep. John Doe (D-State)
"We cannot outsource the ability to make our own medicine and still call ourselves secure."
Read ›
Hon. Pat Sample (Dept. of Example)
"Resilient supply chains run through trusted allies, not single points of failure."
Watch ›
/// Intelligence ///
Latest Analysis
Sample · Live Posts Replace These
Why Medicine Is National Security
The case for treating the discovery and manufacture of American medicine as critical infrastructure.
Read ›
The Two-Front Threat
Pressure from adversary states abroad, policy failure at home, and why both have to be named at once.
Read ›
Diversify to Allies, Not Walls
Why durable supply security runs through trusted networks instead of protectionism.
Read ›
/// Media and Reports ///
What Others Are Saying
Reporting, analysis, and reports that sharpen the case, including coverage featuring ABI. The pieces worth your time, and the starting point for our own.
Content Pending Submissions
Supply Review Flags Single-Source Risk in Key Medicines
Coverage of the foreign dependence problem ABI tracks.
The Case for Ally-Shoring Pharmaceutical Production
External analysis aligned with the diversification argument.
Mapping Foreign Exposure Across the Drug Pipeline
Data worth a closer look, and a future post.
/// Briefs and Papers ///
Policy Briefs
Short, sourced briefs on the policies that decide American biosecurity.
In Production
Biosecurity Readiness Report
The comprehensive assessment of where American biosecurity stands and what it needs.
Coming September
Targeted Controls, Done Right
Why entity-based safeguards beat broad sector-based controls.
In Production
The Domestic Capacity Penalty
How current policy works against the American production it should protect.
In Production